“Decreasing power and authority of the outsourcing role generally. Increasingly sophisticated and skilled CRO business development teams and negotiators. The simple business model of the CRO versus pharma is also affecting PCMG members.” – David Davies
“The outsourcing landscape gets ever more complex with increasing regulation, pressures to deliver faster and do more with less, and with the ever increasing array of external service providers that play a key role in project delivery. The introduction of AI is something that will inevitably change the landscape and an area that we need to be responsive to and adapt accordingly.” – Dave Webber
“One, the threat of replacing people with systems as AI and technology risks automating the selection and management of suppliers and replacing working relationships with processes. Two, the rise and fall (and rise?) of biotechs creating instability and the replacement of FTE outsourcing people with contractors who don’t have long-term commitment/investment to develop and improve best practice (becoming more like the US where we’ve failed to set up PCMG because, I believe, employers and employees’ perspective are limited to short-term, often financial, outcomes. Thirdly, the shift to online interaction instead of F2F meetings. Would online marriage be viable? Then why expect business relationships to work well that way – joyless. Lastly, Trump. The decimation of the US state-sponsored R&D in medical science will increase cost, decrease pipeline and strangle innovation and risk-taking in clinical development.” – Richard Scaife
“Since I joined PCMG the industry has changed in many ways. The rise of procurement functions has impacted outsourcing professionals specialising in clinical trials and the reductions in workforces and restrictions on travel and training are making it challenging for members to attend events and contribute their time.” – Steve Martindill